Mayne Pharma Ltd. (ASX: MYP) has agreed to acquire the remaining worldwide rights to Nipent® (pentostatin for injection) for a total consideration of US $8 million.
Mayne Pharma acquired in August 2006 the North American rights to Nipent® from SuperGen, Inc. (Nasdaq: SUPG), for a total consideration of US $34 million.
According to Dr. James S. Manuso, president and chief executive officer of SuperGen, Inc.:
"The transaction marks the completion of SuperGen's transition to a targeted drug discovery and development company that is powered by a strong balance sheet and a well-fuelled royalty and milestone financial engine. The transition of the Nipent® North American franchise to Mayne Pharma was very efficient. We expect the same withvrespect to transitioning this remaining franchise."
Nipent® is approved for patients with hairy-cell leukaemia.
Find more details from the press release.
[Photo Credit: PennHealth]
Comment Preview